Advertisement

Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B

Published:January 22, 2020DOI:https://doi.org/10.1016/j.jhep.2020.01.007

      Highlights

      • Study conducted in Caucasians with chronic hepatitis B, with or without cirrhosis, after 5 years of entecavir/tenofovir.
      • Age >50 years, baseline cirrhosis and liver stiffness ≥12 kPa at year 5 were independently associated with increased risk of HCC.
      • CAGE-B score based on age at year 5 and baseline cirrhosis in relation to LSM at year 5 reliably predicted HCC risk >5 years.
      • SAGE-B score based only on age and LSM at year 5 was also a reliable predictor of HCC incidence >5 years.

      Background & Aims

      Hepatocellular carcinoma (HCC) may develop in patients with chronic hepatitis (CHB) even after 5 years of oral therapy and cannot be easily predicted. We assessed predictors of HCC development and the need for HCC surveillance in this setting.

      Methods

      Of 1,951 adult Caucasians with CHB included in the PAGE-B cohort, 1,427 (73%) had completed >5 years of follow-up under therapy without developing HCC by year 5. Median follow-up was 8.4 years from treatment onset. Points-based risk scores were developed to predict HCC risk after year 5.

      Results

      In years 5–12, HCC was diagnosed in 33/1,427 (2.3%) patients with cumulative incidences of 2.4%, 3.2% and 3.8% at 8, 10 and 12 years, respectively. Older age or age >50 years, baseline cirrhosis and liver stiffness (LSM) ≥12 kPa at year 5 were independently associated with increased HCC risk. The HCC incidence was lower in non-cirrhotics than cirrhotics at baseline with year-5 LSM <12; among cirrhotics at baseline, it was lower in those with year-5 LSM <12 than ≥12 kPa. CAGE-B score was based on age at year 5 and baseline cirrhosis in relation to LSM at year 5 and SAGE-B score was based only on age and LSM at year 5 (c-index = 0.809–0.814, 0.805–0.806 after bootstrap validation). Both scores offered 100% negative predictive values for HCC development in their low risk groups.

      Conclusions

      In Caucasians with CHB, the HCC risk after the first 5 years of antiviral therapy depends on age, baseline cirrhosis status and LSM at year 5. CAGE-B and particularly SAGE-B represent simple and reliable risk scores for HCC prediction and surveillance beyond year 5 of therapy.

      Lay summary

      In Caucasians with chronic hepatitis B, the risk of hepatocellular carcinoma after the first 5 years of entecavir or tenofovir therapy depends on age, baseline cirrhosis status and liver stiffness at year 5, which can provide simple and reliable risk scores for hepatocellular carcinoma prediction and surveillance beyond year 5. In patients with cirrhosis at baseline, liver stiffness <12 kPa at year 5 is associated with lower HCC risk, but surveillance may be still required.

      Graphical abstract

      Keywords

      Linked Article

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Hepatology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • European Association for the Study of the Liver
        EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection.
        J Hepatol. 2017; 67: 370-398
        • Terrault N.A.
        • Lok A.S.F.
        • McMahon B.J.
        • Chang K.M.
        • Hwang J.P.
        • Jonas M.M.
        • et al.
        Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance.
        Hepatology. 2018; 67: 1560-1599
        • Marcellin P.
        • Gane E.
        • Buti M.
        • Afdhal N.
        • Sievert W.
        • Jacobson I.M.
        • et al.
        Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study.
        Lancet. 2013; 381: 468-475
        • Wong G.L.
        • Chan H.L.
        • Mak C.W.
        • Lee S.K.
        • Ip Z.M.
        • Lam A.T.
        • et al.
        Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis.
        Hepatology. 2013; 58: 1537-1547
        • Lim Y.S.
        • Han S.
        • Heo N.Y.
        • Shim J.H.
        • Lee H.C.
        • Suh D.J.
        Mortality, liver transplantation, and hepatocellular carcinoma among patients with chronic hepatitis B treated with entecavir vs lamivudine.
        Gastroenterology. 2014; 147: 152-161
        • Papatheodoridis G.V.
        • Sypsa V.
        • Dalekos G.
        • Yurdaydin C.
        • Van Boemmel F.
        • Buti M.
        • et al.
        Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population.
        J Hepatol. 2018; 66: 1129-1136
        • Papatheodoridis G.V.
        • Lampertico P.
        • Manolakopoulos S.
        • Lok A.
        Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review.
        J Hepatol. 2010; 53: 348-356
        • Papatheodoridis G.V.
        • Chan H.L.
        • Hansen B.E.
        • Janssen H.L.
        • Lampertico P.
        Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy.
        J Hepatol. 2015; 62: 956-967
        • Vlachogiannakos J.
        • Papatheodoridis G.
        Hepatocellular carcinoma in chronic hepatitis B patients under antiviral therapy.
        World J Gastroenterol. 2013; 19: 8822-8830
        • Lampertico P.
        • Maini M.
        • Papatheodoridis G.
        Optimal management of hepatitis B virus infection - EASL special conference.
        J Hepatol. 2015; 63: 1238-1253
        • Papatheodoridis G.
        • Dalekos G.
        • Sypsa V.
        • Yurdaydin C.
        • Buti M.
        • Goulis J.
        • et al.
        PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy.
        J Hepatol. 2016; 64: 800-806
        • Wong V.W.S.
        • Janssen H.L.A.
        Can we use HCC risk scores to individualize surveillance in chronic hepatitis B infection?.
        J Hepatol. 2015; 63: 722-732
        • Papatheodoridis G.
        • Idilman R.
        • Dalekos G.
        • Buti M.
        • Chi H.
        • Van Boemmel F.
        • et al.
        The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B.
        Hepatology. 2017; 66: 1444-1453
        • Terrault N.A.
        • Bzowej N.H.
        • Chang K.M.
        • Hwang J.P.
        • Jonas M.M.
        • Murad M.H.
        AASLD guidelines for treatment of chronic hepatitis B.
        Hepatology. 2016; 63: 261-283
        • European Association for the Study of the Liver
        • Asociacion Latinoamericana para el Estudio del Higado
        EASL-ALEH clinical practice guidelines: non-invasive tests for evaluation of liver disease severity and prognosis.
        J Hepatol. 2015; 63: 237-264
        • European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer
        EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma.
        J Hepatol. 2012; 56: 908-943
        • Collett D.
        Modelling Survival Data in Medical Research.
        CRC Press, Boca Raton, FL2014
        • Sullivan L.M.
        • Massaro J.M.
        • D'Agostino Sr., R.B.
        Presentation of multivariate data for clinical use: the Framingham study risk score functions.
        Stat Med. 2004; 23: 1631-1660
        • Heagerty P.J.
        • Lumley T.
        • Pepe M.S.
        Time-dependent ROC curves for censored survival data and a diagnostic marker.
        Biometrics. 2000; 56: 337-344
        • European Association for the Study of the Liver
        EASL clinical practice guidelines: management of hepatocellular carcinoma.
        J Hepatol. 2018; 69: 182-236
        • Hadziyannis S.J.
        • Papatheodoridis G.V.
        Hepatitis Be antigen negative chronic hepatitis B – natural history and treatment.
        Semin Liver Dis. 2006; 26: 130-141
        • Wiemann S.U.
        • Satyanarayana A.
        • Tsahuridu M.
        • Tillmann H.L.
        • Zender L.
        • Klempnauer J.
        • et al.
        Hepatocyte telomere shortening and senescence are general markers of human liver cirrhosis.
        FASEB J. 2002; 16: 935-942
        • Chang T.T.
        • Liaw Y.F.
        • Wu S.S.
        • Schiff E.
        • Han K.H.
        • Lai C.L.
        • et al.
        Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B.
        Hepatology. 2010; 52: 886-893
        • Ruggieri A.
        • Gagliardi M.C.
        • Anticoli S.
        Sex-dependent outcome of hepatitis B and C viruses infections: synergy of sex hormones and immune responses?.
        Front Immunol. 2018; 9: 2302
        • Samji H.
        • Yu A.
        • Kuo M.
        • Alavi M.
        • Woods R.
        • Alvarez M.
        • et al.
        Late hepatitis B and C diagnosis in relation to disease decompensation and hepatocellular carcinoma development.
        J Hepatol. 2017; 67: 909-917
        • Sherman M.
        HCC risk scores: useful or not?.
        Semin Liver Dis. 2017; 37: 287-295